Akebia Therapeutics

Akebia Therapeutics

AKBA· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -15.3% in FY2025

John P. Butler is the CEO of Akebia Therapeutics and was paid $5.7M in FY2025 (Dec), up 33%.

Pay$100 in the stock at the end of FY20 → $58
CEO pay is from each Akebia Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives4

See all
  1. 1John P. ButlerFY2025
  2. 2Steven K. BurkeFY2025
  3. 3Erik J. OstrowskiFY2025
  4. 4Nicholas P. GrundFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Akebia Therapeutics paid its 4 named executives $11.0M in total in FY2025 (Dec). CEO John P. Butler was paid $5.7M of that.

Name
John P. ButlerPresident and Chief Executive Officer
Steven K. BurkeM.D., Senior Vice President, Chief Research & Development and Medical Officer
Erik J. OstrowskiSenior Vice President, Chief Financial Officer, Chief Business Officer and TreasurerNot disclosed
Nicholas P. GrundSenior Vice President, Chief Commercial OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2024 (Dec) proxy of Akebia Therapeutics names 20 peer companies for pay. Among Akebia Therapeutics and these peers, CEO pay was 3rd highest of 4 and total shareholder return was the lowest of 4.

3rd highest of 4in Akebia Therapeutics and its pay peers, FY2024 (Dec) by CEO pay:

$4.1M$7.0M

4th highest of 4in Akebia Therapeutics and its pay peers, FY2024 (Dec) by total shareholder return:

$30$259

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Adrian AdamsChair · 7 yr on the boardIndependentCompensation—Paid as an executive
  • Ronald E. FriesonDirector · 4 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
  • Philip J. Vickers, Ph.D.Director · -1 yr on the boardIndependentCompensation, Research & Development—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Akebia Therapeutics CEO pay rose 33% to $5.7M. The stock fell 15% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Akebia Therapeutics CFO pay rose 48% to $1.8M. The stock fell 15% in FY2025 (Dec).
    DEF 14A
  3. Board
    Philip J. Vickers, Ph.D. joined the board of Akebia Therapeutics. Philip J. Vickers, Ph.D. sits on no other public board.
    3
  4. Pay
    Akebia Therapeutics Division head pay rose 49% to $1.8M. The stock rose 53% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Akebia Therapeutics CEO pay rose 54% to $4.3M. The stock rose 53% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Akebia Therapeutics CFO pay fell 39% to $1.0M. The stock rose 53% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Akebia Therapeutics Division head pay fell 12% to $1.2M. The stock rose 115% in FY2023 (Dec).
    DEF 14A
  8. Pay
    Akebia Therapeutics General counsel pay fell 16% to $1.0M. The stock rose 115% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Akebia Therapeutics CFO pay fell 41% to $942.6K. The stock rose 115% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 28, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KMar 13, 2025FY2024
Proxy statementDEF 14AApr 25, 2024FY2023
Annual report10-KMar 14, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data